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had received 3 or more treatment regimens. Prior therapy included
R in half of all patients. 12 patients had never achieved a complete
remission, and 8 had primary refractory disease. Toxicity was
similar to that reported with BEAM alone and included a fall in
DLCO for most patients with 1 patient experiencing a transient
decline to below 50% of the predicted values corrected for hemo-
globin. Grade III/IV toxicities included infection, fever, stomatitis,
nausea, vomiting, diarrhea, hemorrhage, and edema. One patient
at the 700 cGy level developed veno-occlusive disease which con-
stituted a dose-limiting toxicity (maximum total bilirubin 10.4),
necessitating the enrollment of 3 additional patients at that dose
level. Ascites resolved by D 34, and total bilirubin was normal by
D 60. At the 700 cGy level, administered radioactivities ranged
from 0.27 to 0.73 mCi/kg (median: 0.37), and the total body dose
from 43 to 12 cGy (median: 99 cGy). In all but one case, the critical
organ was the liver. Engraftment by ABMTR criteria occurred at
a median of 10 days (range: 8-18) for 1000 granulocytes and 21
days (range: 12-40) for platelet recovery to 20,000. With a median
follow-up of 12 months, the OS is 60% at 3 years. PFS is 47% at
both 2 and 3 years. Accrual continues at the 900 cGy dose level
which is anticipated to require greater than the .4 mCi/kg dose of
90 Y Zevalin recommended for conventional treatment.
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Allogeneic BMT offers a cure to select patients with sickle cell
disease (SCD), but the limited available long-term data and con-
cerns about the risk-to-beneﬁt ratio present dilemmas for families
and clinicians. We report favorable outcomes in a large single
institution experience with myeloablative matched sibling BMT
for children with severe SCD between December 1993 and April
2003. Sixteen patients (12 male) with a median age 7.7 years
(3.3-17.1) were transplanted for primary indications of CVA (n 
8), recurrent TIA (n  1), recurrent ACS (n  6), and frequent
VOC pain (n  1). Graft source was HLA-identical sibling mar-
row, with 9 HgbAS donors. Preparative regimen (BU 14 mg/kg,
CTX 200 mg/kg, ATG 90 mg/kg) was well tolerated. Special
measures included aggressive management of hypertension and
hypomagnesemia, maintenance of Hgb 10-12 g/dl and platelets
50k, and prolonged antiepileptics while on CSA for GVHD
prophylaxis. The initial 8 patients were treated on a multicenter
consortium trial (Walters et al). With median follow-up 36 months
(6-84), OS and DFS are 100% and there are no graft failures. Two
patients have stable mixed chimerism (72 and 69% donor) with low
HgbS (0 and 2.5%) and no clinical SCD. Median WBC engraft-
ment was day 12.5 (10-21) and platelet engraftment day 31.5
(17-46). No patients experienced aGVHD. The two oldest patients
had cGVHD related to medication non-compliance. Two of the 8
patients with prior CVA had serious CNS events, including seizure
and hemorrhage on day 0 in a moya-moya patient and late pro-
gressive cerebrovascular disease in a patient with prior CVA. None
had new clinical CVA. One patient (age 16.7 years) without prior
CVA had a seizure attributed to “non-compliance rebound” with
CSA. Infections included two episodes of Zoster, one early mul-
tiorganism bacteremia, and one late pneumococcal bacteremia. All
patients have excellent functional status and attend school/college.
These favorable outcomes have led our center to offer this trans-
plant treatment as a standard-of-care with principles speciﬁc to
SCD: 1)careful psychosocial screening and transplantation at a
young age, 2)supportive measures to avoid CNS events, and 3)
long-term follow-up with attention to infection and cerebrovascu-
lar disease that may relate to SCD rather than the BMT. In our
experience, collaborative management with a comprehensive sickle
cell program optimizes referral of appropriate patients, reduces
peritransplant complications, and optimizes outcomes.
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Background: BMT from a histocompatible sibling is the treat-
ment of choice for young pts with SAA. Those who have received
few transfusions can achieve long term survival after conditioning
with Cyclophosphamide 200mg/kg (CY200). For pts heavily trans-
fused, graft failure (GF) after this regimen is high and led to the
addition of Anti-lymphocyte globulin to improve outcome. Unfor-
tunately this drug is not easily available in developing countries and
from 01/03 on, all pts with more than 15 transfusions pre-BMT
were given Busulfan 12mg/kg (BU12) and CY 120mg/kg (CY120).
Material and Methods: Between 10/79 and 09/03,396 pts with
SAA were transplanted at our BMT Unit. In this study we per-
formed a retrospective analysis in 171 pts 21 years, who received
an HLA-identical sibling transplant (bone marrow), and metho-
trexate  cyclosporine as GVHD immuneprophylaxis. All pts
received prophylactic antibiotics according to common practice.
Preparatory regimen: CY200: 92 pts and BU12/CY120: 79 pts.
Median age at transplant: 13yr (range 1 – 20yr). Gender: 64F/
107M. Median disease duration: 3m (range: 0-232m). Median
transfusions pre-BMT: 23UI (range: 0-238). TNC: 1, 48–12, 9 
108/kg (M: 3, 36). Results: 122 pts are alive and well 263-6141
days post-BMT (M: 2664 days). In the CY200 group 40 pts re-
ceived 15 transfusions and 34 were evaluable for engraftment: 2
pts had primary GF and 20 had late GF (Median: 288 days; range:
100-734 days post-BMT). Mucosytis occurred in 9/92pts.
A-GVHD grade III-IV occurred in 3/84 evaluable pts and exten-
sive C-GVHD in 2/78pts. Estimated overall survival in 16 years is
86% for pts15 transfusions and 50% for pts15 transfusions. In
the BU12/CY120 group, 76 pts were evaluable for engraftment, 1
pt had primary GF and 11 had late GF (median: 524 days post-
BMT). Mucosytis grade III-IV occurred in 27 pts. 8/76pts had
A-GVHD grade III-IV and 8/72pts had extensive C-GVHD. Es-
timated overall survival in this group is 70% (P value  0.002).
Forty-nine pts are dead: Bu12/CY120: 22 pts, CY200  15: 20pts
and CY200  15: 7 pts). .Causes of death in both groups were
mainly related to infection. Conclusion: The BU12  CY120
regimen decreased the GF rate and improved overall survival for
pts heavily transfused but it was associated with more toxicity and
higher transplant related mortality.
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LESSONS FROM A POSITIVE RANDOMIZED TRIAL OF HIGH-DOSE CHE-
MOTHERAPY IN METASTATIC BREAST CANCER: LEARN FROM OUR
MISTAKES, BUILD ON OUR SUCCESSES, DRAIN THE BATHWATER,
HOLD THE BABY
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